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The Usefulness of Aqueous Fluid Analysis for
Epstein–Barr Virus in Patients with Uveitis
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ABSTRACT
Purpose: To determine characteristics of patients with laboratory ﬁndings indicative of intraocular Epstein–Barr-virus
(EBV) infection and to establish the usefulness of the laboratory analysis in patients with uveitis.
Methods: Retrospective study of patients who underwent diagnostic aqueous ﬂuid analysis. Diverse demo-
graphic data of patients were registered.
Results: EBV-PCR tested positive in 3/201 (1%) and EBV-GWC in 22/245 (9%). The prevalence of immuno-
suppression was similar in EBV positive (by PCR/GWC) and EBV negative patients (7/25; 28% vs. 50/272;18%,
P = 0.29). Out of all 22 EBV-GWC positive patients, GWC was between 3 and 10 in 91%. In total, 14 patients had
laboratory results indicating only EBV infection. Patients without an alternative explanation for uveitis (6/14;
43%) had a chronic recurrent course and good visual prognosis.
Conclusion: Low EBV-GWC values combined with multiple positive GWC and/or PCR for other infectious
agents. Intraocular assessment for EBV in the initial examination of uveitis patients has limited value.
Keywords: Aqueous ﬂuid analysis, clinical picture, Epstein–Barr virus, uveitis, visual prognosis
The association between uveitis and Epstein–Barr virus
(EBV) infection poses an enigma. Previous case reports
and case series link EBV to various forms of uveitis, from
bilateral granulomatous anterior uveitis to acute retina
necrosis.1–3 Most reports based the association between
uveitis and EBV infection on positive serologic results,
suggesting concurrent active systemic EBV infection.1,3,4
Subsequently, more systematic reports emerged
on this presumed association, reporting on polymer-
ase chain reaction (PCR) positive for EBV in aqueous
ﬂuid of uveitis patients (up to 17%); however, these
positive PCR results were also found in uveitis of
other established causes and even in non-uveitis eyes
(7%), especially in patients with severe ocular disor-
ders and break down of blood–retina barrier.4–12 In
one study examining the viral loads of EBV PCR
positive patients, intraocular viral loads were always
lower when compared to blood levels, which does
not support the presumptive replication of EBV
within the eye.13,14
Herein we report on a large series of uveitis patients
who underwent diagnostic intraocular ﬂuid assessment
by both PCR and GWC for EBV in addition to Herpes
Simplex Virus (HSV), Varicella Zoster Virus (VZV),
Cytomegalovirus (CMV), Rubellavirus (RV) and report
on the clinical characteristics of patients with laboratory
ﬁndings indicative of intraocular EBV infection.
METHODS
Patients and Data Collection
All patients who underwent diagnostic aqueous ﬂuid
analysis between January 2010 and October 2016 at the
Ophthalmology department of the Erasmus Medical
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Center (EMC, Rotterdam, the Netherlands) were
included in this retrospective cohort study, which was
approved by the Medical Ethics Committee and adheres
to the Tenets of the Declaration of Helsinki (MEC-
2012–016). We reviewed the medical records of all
patients who had positive results in PCR or GWC for
EBV.15
An aqueous ﬂuid tap was performed in patients
with a suspicion of infection (the presence of uveitis
with or without small/medium sized keratic preci-
pitates (KPs), some form of iris abnormalities, high
intraocular pressure (IOP), and resistance to ster-
oids and non-conclusive results of initial uveitis
work-up). Aqueous analysis was also performed
before initiating systemic immunosuppressive treat-
ment in patients with uveitis of unknown cause
despite a standardized diagnostic investigation pro-
tocol (consisting of radiologic chest imaging, ery-
throcyte sedimentation rate, blood counts, serum
angiotensin-converting enzyme levels, serology for
syphilis as well as interferon gamma release assay
(IGRA) test (QuantiFERON–TB Gold In-Tube test;
(quantiferon; Cellestis Limited, Carnegie, Victoria,
Australia)) and in those with anterior and panuvei-
tis also Human Leukocyte Antigen B27 testing).
A diagnostic panel of PCR and GWC was deter-
mined in all diagnostic taps, which included assess-
ment for HSV, VZV, CMV, RV, and EBV. Additionally,
quantitative EBV PCR analysis in peripheral blood was
performed in the patients who tested positive by PCR
for EBV in aqueous ﬂuid.
In patients with laboratory indicators of EBV-
associated uveitis, we registered diverse demographic
and clinical data including gender, age at onset of uveitis,
location and clinical features of uveitis and any systemic
and ocular co-morbidity. The anatomical localization of
uveitis was deﬁned according to the Standardization of
Uveitis Nomenclature.16 The cause of uveitis, whenever
known (and other than EBV), was also registered.
Sample Collection and Processing
The ocular ﬂuid samples were stored at −80°C and
serum samples at +4°C until processing for laboratory
analysis.
Determination of Intraocular Antibody Production:
Speciﬁc immunoglobulin G (IgG) titers against RV,
HSV, VZV, CMV, and EBV in serum and aqueous
humor were determined with the Euroimmun
(Luebeck, Germany) indirect immunoﬂuorescence
test kit. The immunoﬂuorescence assays (IFAs) are
based on biochips, which were coated with the virus
speciﬁc-infected cells. Serial tenfold dilutions (1:10 to
1:5120) were prepared in sample buffer (Euroimmun).
Samples were applied to the reaction ﬁelds of
a reagent tray. After incubation for 30 min, slides
were rinsed and immersed with phosphate-buffered
saline (PBS). For detection of bound antibodies, slides
were placed on reagent trays prepared with ﬂuores-
cein conjugated antihuman immunoglobulin of the
IgG class. Following a 30-min incubation, slides
were washed as described above, embedded with
mounting medium, cover slipped and evaluated by
ﬂuorescence microscopy.
IgG1 titres in serum and ocular ﬂuid were deter-
mined using speciﬁc enzyme-linked immunosorbent
assay (ELISA) kit (PeliClass human IgG subclass kit,
Sanquin, Amsterdam, the Netherlands). The GWC
was calculated as follows: GWC = ((speciﬁc IgG
eye/speciﬁc IgG serum)*(IgG1 serum/IgG1 eye)).
Values exceeding 3 are considered indicative of
intraocular antibody production.
Real-Time Taqman assay was performed as described
previously.17 For CMV, EBV, HSV1 and 2, rubella and
VZV total nucleic acid was extracted from ocular ﬂuid
using theMagNaPure LCTotalNucleic Acid isolation kit
(Roche, Almere, The Netherlands) with an input volume
of 200 µL (50 μL of the ocular ﬂuid samplewas 4x diluted
in RPMI-1640 (Lonza)) and output volume of 100 μL. The
extraction was internally controlled by the addition of
a known concentration of phocine distemper virus
(PDV) for RNA viruses and PhHV (Phocine herpes
virus) for DNA virus.
Twenty μL extracted RNA was ampliﬁed in 50-μL
ﬁnal volume, containing 12.5-μL 4 × TaqMan Fast Virus
1-Step Master Mix (including (1 U/μL) uracil-
N-glycosylase, Life Technologies, Nieuwerkerk a/d
IJssel, the Netherlands), and 1 μL of a primers and
probe mixture. For DNA viruses 5 µL of triﬂuoroacetic
acid (TFA) and 0.4 μL of primers and probe mixture was
ampliﬁed in a 20-μL ﬁnal volume. For CMV a dual target
PCR was used.17,18 For EBV, HSV1 and 2 and VZV
primers were adapted from our earlier published proce-
dure using real-time technique. Rubella RNAwas ampli-
ﬁed using forward primer (5ʹ-cgtccagcaccctcacaag-3ʹ),
reverse primer (5ʹ-cggagagttgccagacggt-3ʹ) and probe
(FAM-cgtccgggtcagttccatacagaga-BHQ-1). The RT-PCR
temperature proﬁle was 5 min at 50°C, 20 sec at 95°C,
45 cycles of 3 s at 95°C and 30 sec at 60°C. Ampliﬁcation
was performed in an LC480 II(Roche Applied Science,
Almere, the Netherlands) using the Fit Point analysis
module. Quality assurance was performed using
QCtoday software. The criterion for a successful RT-
PCR run was that cycle threshold (Ct) values of both
internal control and positive RT-PCR control should be
within 3 × standard deviation (SD) of the mean.
RESULTS
In total, 297 uveitis patients underwent an aqueous ﬂuid
tap out of which 201/297; 68% were tested for EBV-PCR
and 245/297; 82% were tested for EBV-GWC (Table 1).
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Both assays were simultaneously performed in 184/297;
62% patients.
EBV-PCR tested positive in 3/201 (1%) and EBV-
GWC in 22/245; 9%, resulting in 25 patients positive
in intraocular ﬂuid by at least one laboratory method
for EBV. The total follow-up from aqueous ﬂuid tap
until last visit at our center of these patients was
2.5 ± 1.9 years). Out of these, 60% were of Caucasian
origin and 64% were female. Further 28% were immu-
nocompromised (immunosuppressive medication in
12% and human immunodeﬁciency virus (HIV)-
positivity in 16%). The prevalence of immunosup-
pression was similar in EBV positive (either by PCR
or GWC) and EBV negative patients (7/25; 28% vs.
50/272;18%, P = 0.29, χ2 test). The mean age at onset
of uveitis and distribution of anatomical localizations
of uveitis was similar between EBV positive and EBV
negative patients (Table 2).
The basic characteristics of patients positive for EBV
PCR in intraocular ﬂuid (N = 3) are given in Table 3. Two
of these three patients also tested positive by PCR for
another infectious agent in aqueous and the clinical pic-
ture ﬁtted the diagnosis of that particular infectious
agent. The patient without any evidence of another
infectious agent in PCR or GWC and no alternative diag-
nosis had bilateral multifocal choroiditis and was not
immunocompromised. The blood sample of this patient
was negative in EBV PCR (<100 IU/mL). One of these
three PCR-positive patients in aqueous had also a EBV
PCR positive blood sample, though with very low but
detectable viral loads; this patient was immunocompro-
mised by HIV infection (Table 3).
Twenty-two patients tested positive for EBV by
GWC (Table 4). Out of these, 7 had multiple positive
GWC’s, 3 were positive by PCR for another infectious
agent, and 12 patients were positive only for EBV
(Table 3). Out of all 22 EBV-GWC positive patients,
GWC was between 3 and 10 in 91%. The two patients
with higher GWC (≥10) were diagnosed with sarcoi-
dosis (one of which was also HIV positive). The aqu-
eous IgG titers for EBV were typically low, the exact
titers in aqueous and serum are given in the supple-
mentary Table. The majority of GWC positive patients
77% had another explanation of their uveitis than
EBV. Out of these, 29% was caused by various infec-
tions and the remaining patients were diagnosed with
associated non-infectious systemic diseases (mostly
sarcoidosis, 29%).
TABLE 1. Results of intraocular ﬂuid analyses of 297 patients with uveitis.
Positive PCR in
tested patients
Positive GWC
(≥3)
in tested
patients
Positive GWC (≥3 but
<10) in tested patients
Positive (GWC ≥10)
in tested patients
Positive PCR and GWC
(≥3.0) in tested patients
Herpes simplex virus 10/271 (4%)* 1/257 (<1%) 1/1 (100%) 0 0
Varicella zoster virus 9/271 (3%) 19/258 (7%) 11/19 (58%) 8/19 (42%) 7/245 (3%)
Cytomegalovirus 12/248 (5%) 13/252 (4%) 10/13 (77%) 3/13 (23%) 2/227 (1%)
Epstein–Barr virus 3/201 (1%) 22/245 (9%) 20/22 (91%) 2/22 (9%) 0
Rubella virus 9/183 (5%) 29/192 (15%) 8/29 (28%) 21/29 (72%) 7/167 (4%)
Toxoplasma gondii 6/120 (5%) 12/106 (11%) 6/12 (50%) 6/12 (50%) 3/101 (3%)
PCR, polymerase chain reaction; GWC, Goldmann–Witmer coefﬁcient.
*9/271 (3%) Herpes simplex virus type 1 and 1/272 (<1%) Herpes simplex virus Type 2.
TABLE 2. Characteristics of patients tested for Epstein–Barr virus in intraocular ﬂuids.
Total PCR and/or GWC negative PCR positive for EBV GWC positive for EBV
Number 297 272/297 (92%) 3/297 (1%) 22/297 (7%)
Age at onset
uveitis (mean
years ± SD)
46.4 (±18.8) 46.9 (±18.8) 50.7 (±11.8) 40.0 (±17.5)
Gender
Male 121/297 (41%) 112/272 (41%) 1/3 (33%) 8/22 (36%)
Female 176/297 (59%) 160/272 (59%) 2/3 (67%) 14/22 (64%)
Anatomical localization
Anterior 97/297 (33%) 93/272 (34%) 0 4/22 (18%)
Intermediate 26/297 (9%) 26/272 (10%) 0 0/22 (5%)
Posterior 84/297 (28%) 82/272 (30%) 1/3 (33%) 1/22 (5%)
Panuveitis 82/297 (28%) 65/272 (24%) 2/3 (67%) 15/22 (68%)
Scleritis 8/297 (3%) 6/272 (2%) 0 2/22 (9%)
EBV, Epstein–Barr virus; PCR, polymerase chain reaction; GWC, Goldmann–Witmer coefﬁcient; SD, standard deviation.
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In total, 14 patients had laboratory results indi-
cating only EBV infection (either 1. positive EBV-
PCR with negative results for PCR and/or GWC for
other viruses or 2. a negative EBV-PCR but GWC
positive for EBV and in cases with multiple positive
coefﬁcients, GWC for EBV had the highest value).
Out of these, eight (57%) patients had another
explanation for their uveitis. The GWC values of
these patients were between 3 and 10 in six of
eight patients. No alternative explanation for uveitis
was found in six (43%) patients. Three of these
patients exhibited solely anterior chamber inﬂam-
mation mostly with small KPs and marked involve-
ment of the vitreous. Their vitritis was severe
(requiring pars plana vitrectomy in two) but had
no documented inﬂammatory involvement of the
retina and/or choroid.16 The remaining three
patients had solely anterior chamber inﬂammation
without vitreous and/or choroido-retinal involve-
ment. All of these six patients had a chronic recur-
rent course of inﬂammations and good visual
prognosis (all affected eyes had visual acuity at
least of 20/20 at last follow-up. Only one of these
six patients required systemic immunosuppressive
treatment. The inﬂammation was bilateral in four of
six patients and no other common characteristics
were found. None of these six patients had aqueous
ﬂuid tap performed within 3 months after uveitis
onset and their serum IgG levels for EBV were
diverse (supplementary Table).
None of the 25 patients PCR and/or GWC positive
patients for EBV had lymphoma at the onset of uveitis
and/or was diagnosed with (intraocular) lymphoma
during follow-up.
DISCUSSION
Our results show that EBV PCR and/or GWC can be
detected in intraocular ﬂuids of patients with uveitis
of diverse origins and do not support a high preva-
lence of EBV-induced uveitis. Moreover, the positive
EBV results of PCR and GWC in intraocular ﬂuids
were commonly combined with other positive results
for infectious agents and the GWC levels were typi-
cally low.
In case series from 1990, EBV was considered as
a possible cause of granulomatous anterior uveitis in
a case series of three patients based on detectable IgG
antibody titers against viral capsid antigen (VCA) in
aqueous ﬂuid. However, GWC was not calculated
(but would have been <3.0 in two of these three
patients) and PCR analyses for EBV were not
performed.1 Other reports supported the presumed
association of EBV with uveitis by documenting posi-
tive serum and/or aqueous ﬂuid antibody levels,
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suggesting concurrent active systemic EBV infection.
1,3,4,19
A more systematic study by Ongkosuwito et al.
reported on the presence of EBV PCR in intraocular
ﬂuid (positive in 25/183;14% patients of uveitis) and
GWC (positive in 3/82; 4%) in uveitis patients. Out of
25 EBV-PCR positive patients, nine (36%) were
immunocompromised.5 All three GWC positive
patients did not match the clinical picture described
in the initial case series (bilateral anterior granuloma-
tous uveitis).1,4,5 In addition, PCR positive for EBV
was also detected in cataract controls (3/46; 7%)
while GWC remained negative (none in 20 tested).5
Successive studies reported on positive EBV PCR
patients and their intraocular loads, which were always
lower when compared to blood. The only exception
consisted of two patients with AIDS and primary cen-
tral nervous system (CNS)/intraocular non-Hodgkin’s
lymphoma.13,14 These previous ﬁndings show that
intraocular replication of EBV in uveitis still remains to
be proven. In addition, none of the patients exhibited
simultaneous PCR and GWC for EBV.
Our study reports the results on simultaneous
testing of EBV by PCR and GWC in 184 patients
with uveitis. We noted a lower PCR yield for EBV
(3/201; 1%) when compared to previous literature
(up to 17%).5,6,13,14 The prevalence of GWC was not
systematically performed in the past except one
study, which reports on 3/82; 4% prevalence of posi-
tive EBV GWC in uveitis patients (out of which 1 had
a higher GWC for VZV), which is similar to 9%
found in the present study.5 It should be however
noted that the GWC results in our study were typi-
cally low and/or combined with multiple positive
GWCs.
One explanation for the multiple positive GWCs
might be a polyclonal stimulation of lymphocytes. In
our series, one third of GWC positive patients had mul-
tiple positive coefﬁcients (most commonly for VZV),
which was also previously noted.5,20–22 The other pos-
sibilitymight be the sensitivity of the GWC technique as
the values for EBV were commonly low. The GWC is
based on ratio of speciﬁc IgG levels in serum and aqu-
eous and one should be aware of the caveats when
interpreting the coefﬁcient. Speciﬁcally, in low intrao-
cular antibody titers for EBV (supplementary Table) one
additional dilution stepwould result in a negativeGWC
value. Table 1 again illustrates this, showing that GWC
for EBV having rather lower values in 91% of cases. This
indicates that evaluation of the marginally positive
GWC results should be carefully made and the exact
levels of intraocular and serum antibodies should also
be evaluated and included in the interpretation of
GWC. Positive EBV PCR ﬁndings might be explained
bymigration of EBV infected lymphocytes into the eye .
Additionally, the disruption of the blood–aqueous bar-
rier might also play a role, especially in PCR positive
cases. This phenomenon is supported by previous stu-
dies, in which PCR was more often positive for EBV in
HIV positive patients with large areas of retinitis com-
pared to cataract controls.5,6 The common prevalence of
immunosuppression (by HIV or immunosuppressive
medication) in patients with positive PCR for EBV in
intraocular ﬂuids was made earlier.6,13,14 In our study,
solely 3 patients were PCR positive out of whom one
was immunosuppressed; this limited number precludes
any meaningful comparisons.
Our study describes 9% prevalence of low positive
EBV GWC results but usually in combination with
multiple positive GWC and/or PCR for other infec-
tious agents. Most patients had another explanation of
uveitis and few patients had only EBV GWC as evi-
dence for cause of their disease. Uveitis in the latter
group was mostly nonspeciﬁc and had good visual
prognosis. We conclude that performing intraocular
assessment for EBV as part of an initial examination
of intraocular ﬂuids has limited value.
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